XNAS
HSIC
Market cap9.53bUSD
Oct 08, Last price
84.63USD
1D
1.16%
1Q
0.27%
Jan 2017
42.25%
Name
Henry Schein Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
Related entities
Subsidiaries (29)
Abic Polska Spolka z ograniczona odpowiedzialnoscia
ALTATEC GMBH
ANIMAL HEALTHCARE SERVICES LIMITED
ARSEUS LAB B.V.
CAMLOG BIOTECHNOLOGIES GMBH
Cliniclands AB
COVETRUS IE LIMITED
DENTAL TREY - SOCIETA' A RESPONSABILITA' LIMITATA
HENRY SCHEIN ANIMAL HEALTH HOLDINGS LIMITED
HENRY SCHEIN DENTAL B.V.
HENRY SCHEIN DENTAL DEUTSCHLAND GMBH
HENRY SCHEIN ESPAÑA SL.
HENRY SCHEIN EUROPEAN HOLDING B.V.
HENRY SCHEIN EUROPEAN SERVICES B.V.
HENRY SCHEIN FRANCE SCA
HENRY SCHEIN GMBH
HENRY SCHEIN HOLDING GMBH
HENRY SCHEIN KRUGG S.R.L.
HENRY SCHEIN ONE UK LIMITED
HENRY SCHEIN PMS B.V.
Key people
Joseph Herring
Independent Director · since 2016
Independent Director · since 2025
Kurt Kuehn
Independent Director · since 2016
Max Lin
Independent Director · since 2025
Anne Margulies
Independent Director · since 2018
Scott Serota
Independent Director · since 2021
Bradley Sheares
Independent Director · since 2010
Independent Director · since 2021
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
135 DURYEA RD
MELVILLE, NY 11747
US
MELVILLE, NY 11747
US
Previous name
HENRY SCHEIN USA, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2021‑12 | 2020‑12 | 2020‑12 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||||
Revenues | |||||||||||||||
Cost of revenue | |||||||||||||||
Unusual Expense (Income) | |||||||||||||||
NOPBT | |||||||||||||||
NOPBT Margin | |||||||||||||||
Operating Taxes | |||||||||||||||
Tax Rate | |||||||||||||||
NOPAT | |||||||||||||||
Net income | |||||||||||||||
Dividends | |||||||||||||||
Dividend yield | |||||||||||||||
Proceeds from repurchase of equity | |||||||||||||||
BB yield | |||||||||||||||
| Debt | |||||||||||||||
Debt current | |||||||||||||||
Long-term debt | |||||||||||||||
Deferred revenue | |||||||||||||||
Other long-term liabilities | |||||||||||||||
Net debt | |||||||||||||||
| Cash flow | |||||||||||||||
Cash from operating activities | |||||||||||||||
CAPEX | |||||||||||||||
Cash from investing activities | |||||||||||||||
Cash from financing activities | |||||||||||||||
FCF | |||||||||||||||
| Balance | |||||||||||||||
Cash | |||||||||||||||
Long term investments | |||||||||||||||
Excess cash | |||||||||||||||
Stockholders' equity | |||||||||||||||
Invested Capital | |||||||||||||||
ROIC | |||||||||||||||
ROCE | |||||||||||||||
| EV | |||||||||||||||
Common stock shares outstanding | |||||||||||||||
Price | |||||||||||||||
Market cap | |||||||||||||||
EV | |||||||||||||||
EBITDA | |||||||||||||||
EV/EBITDA | |||||||||||||||
Interest | |||||||||||||||
Interest/NOPBT | |||||||||||||||